Advertisement

The Latest

Musculoskeletal (MSK) conditions now cost the U.S. more than $420 billion, yet many payer-led interventions fail to engage patients early enough to prevent low-value procedures and rising costs. This new report from TailorCare shows what happens when patients are guided…

Presented by:

Presented by

A federal policy that went into effect Sept. 21 will require employers to pay a $100,000 fee to sponsor highly skilled workers from other countries.  This policy, however, may disproportionately impact areas in the U.S. already facing severe healthcare shortages,…

Regional anesthesia is moving from “nice to have” to a core component of orthopedic care by easing pain, accelerating recovery and expanding what’s possible in outpatient surgery. Yet many groups leave clinical and financial value on the table due to…

Presented by:

Presented by

Nearly half of hospital revenue cycle leaders say denials are their top financial concern — outranking labor shortages, reimbursement cuts and analytics gaps. While many teams focus on rework, high-performing hospitals are looking upstream. This short report offers 10 strategies…

Presented by:

Presented by

The rapid expansion of private equity’s influence in healthcare has impacted competition, affordability, safety and worker welfare in the industry, according to a report published by the Center for American Progress Oct. 30.  According to a February report by Cherry…

Dublin, Ohio-based Cardinal Health, long known for distributing pharmaceuticals and medical products, has rapidly expanded into physician services, making three major, billion-dollar acquisitions in the past two years.  The company is now positioning itself as a serious player in the…

Managing locum tenens at scale is rarely efficient. For one Mid-Atlantic academic medical center, a fragmented approach led to high costs, siloed departments and internal competition for providers. But a centralized, vendor-neutral strategy changed everything. By overhauling its locum tenens…

Presented by:

Presented by

More than 200 industry leaders have spoken: the 2025 Trends in Specialty Drug Benefits Report, co-sponsored by Genentech and Pharmaceutical Strategies Group (PSG), is here. This executive summary captures how payers are resetting specialty drug strategies and what that means…

Presented by:

Presented by
Advertisement